Correlation Between Crinetics Pharmaceuticals and Ultragenyx

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and Ultragenyx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and Ultragenyx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crinetics Pharmaceuticals and Ultragenyx, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and Ultragenyx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of Ultragenyx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and Ultragenyx.

Diversification Opportunities for Crinetics Pharmaceuticals and Ultragenyx

-0.42
  Correlation Coefficient

Very good diversification

The 3 months correlation between Crinetics and Ultragenyx is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and Ultragenyx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ultragenyx and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with Ultragenyx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ultragenyx has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and Ultragenyx go up and down completely randomly.

Pair Corralation between Crinetics Pharmaceuticals and Ultragenyx

Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to generate 0.95 times more return on investment than Ultragenyx. However, Crinetics Pharmaceuticals is 1.05 times less risky than Ultragenyx. It trades about -0.03 of its potential returns per unit of risk. Ultragenyx is currently generating about -0.21 per unit of risk. If you would invest  5,715  in Crinetics Pharmaceuticals on August 27, 2024 and sell it today you would lose (109.00) from holding Crinetics Pharmaceuticals or give up 1.91% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Crinetics Pharmaceuticals  vs.  Ultragenyx

 Performance 
       Timeline  
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Crinetics Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Ultragenyx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Crinetics Pharmaceuticals and Ultragenyx Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Crinetics Pharmaceuticals and Ultragenyx

The main advantage of trading using opposite Crinetics Pharmaceuticals and Ultragenyx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, Ultragenyx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultragenyx will offset losses from the drop in Ultragenyx's long position.
The idea behind Crinetics Pharmaceuticals and Ultragenyx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios